Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM - Get Free Report) have received an average rating of "Moderate Buy" from the five ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $11.40.

A number of equities research analysts recently weighed in on ATNM shares. StockNews.com cut Actinium Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday. HC Wainwright lowered their target price on Actinium Pharmaceuticals from $50.00 to $4.00 and set a "buy" rating for the company in a research note on Tuesday, August 6th. B. Riley cut Actinium Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their target price for the company from $16.00 to $2.00 in a research note on Wednesday, August 7th. Finally, Maxim Group lowered their target price on Actinium Pharmaceuticals from $30.00 to $5.00 and set a "buy" rating for the company in a research note on Tuesday, August 6th.

Actinium Pharmaceuticals Stock Down 6.7 %

NYSE:ATNM traded down $0.13 during mid-day trading on Tuesday, hitting $1.80. 226,050 shares of the company's stock traded hands, compared to its average volume of 446,925. The firm's 50 day moving average price is $1.80. Actinium Pharmaceuticals has a 12 month low of $1.33 and a 12 month high of $10.24. The company has a market capitalization of $56.16 million, a price-to-earnings ratio of -1.28 and a beta of 0.14.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its stake in shares of Actinium Pharmaceuticals by 23.4% during the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company's stock worth $293,000 after acquiring an additional 7,525 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in Actinium Pharmaceuticals during the 2nd quarter worth approximately $92,000. Bank of New York Mellon Corp grew its position in Actinium Pharmaceuticals by 28.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company's stock worth $639,000 after purchasing an additional 19,035 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Actinium Pharmaceuticals during the 2nd quarter worth approximately $142,000. Finally, Interchange Capital Partners LLC purchased a new stake in Actinium Pharmaceuticals during the 3rd quarter worth approximately $37,000. 27.50% of the stock is owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).